Dossier assessment

Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A24-101
Last updated

Report documents

  1. Extract of dossier assessment

    Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 183 kB, DE, not accessible
  2. Dossier assessment

    Binimetinib and encorafenib (NSCLC) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 879 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A24-101

Dossier assessment

Indication:

Adult patients with advanced non-small cell lung cancer with a rapidly accelerated fibrosarcoma isoform B V600E mutation

Result of dossier assessment:
  • Patients with PD-L1 expression ≥ 50%, first-line treatment: added benefit not proven.
  • Patients with PD-L1 expression < 50%, first-line treatment: added benefit not proven.
  • Patients after first-line treatment: added benefit not proven.

Project details

Project no.
A24-101
Commission
Commission awarded on 26.09.2024 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A24-101

Connected Projects

  1. Dossier assessment

    Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-56
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-61
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Encorafenib (colorectal cancer, first line) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A26-88
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form